SurModics Inc., a provider of medical device and in vitro diagnostic technologies, announced financial results for the third quarter of fiscal year 2025, which ended on June 30, 2025. The company reported a total revenue of $29.6 million, marking a 3% decrease compared to the same period in the previous year. However, when excluding the _SurVeil™_ drug-coated balloon license fee revenue, the company noted a 1% year-over-year increase in total revenue. The GAAP net loss was reported at $5.3 million, an improvement from the $7.6 million loss in the previous year. Adjusted EBITDA showed positive movement, increasing to $3.4 million from $1.6 million in the third quarter of fiscal 2024. SurModics also updated its fiscal year 2025 financial guidance, raising its total revenue expectations to a range of $116.5 million to $118.5 million, reflecting a 6% to 8% decrease compared to fiscal 2024. Excluding _SurVeil_ DCB license fee revenue, the expected total revenue is projected to be between $115.0 million and $117.0 million, indicating a more moderate decrease of 3% to 5% compared to the prior fiscal year. The company continues to work towards completing the pending acquisition by an affiliate of GTCR, despite challenges presented by an FTC administrative complaint and federal court action.